MRNA · 8-K · 20260708PR000134

Leadership Transition

Moderna, Inc. · 2026-07-08 · Importance 30 · Surprise 42

Moderna appointed Michael McDonnell to its Board of Directors effective July 8, 2026, and added him to the Board’s Audit Committee. McDonnell served as Biogen’s Executive Vice President and Chief Financial Officer from August 2020 through February 2025, overseeing treasury, accounting, tax, internal audit, procurement, information technology, and business-unit finance. He has more than 35 years of financial leadership experience, including more than 24 years as a public-company chief financial officer, and currently serves on the boards of Merit Medical Systems and Baxter International.

Key facts

• Moderna, Inc. appointed Michael McDonnell to its Board of Directors, effective July 8, 2026. source
• Michael McDonnell will serve on Moderna's Board Audit Committee. source
• Moderna describes itself as a pioneer and leader in the field of mRNA medicine. source
• Moderna states that since its founding, its mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. source
• The press release was issued from Cambridge, Mass., on July 8, 2026. source
• Moderna's stock ticker is NASDAQ: MRNA. source
• The press release states Michael McDonnell brings more than 35 years of financial leadership and public company experience. source
• The press release states Mr. McDonnell has more than 24 years serving as chief financial officer of public companies. source